Supporting innovative research to improve prostate cancer treatment
Official title: Developmental Research Program
Funded at Dana-Farber Cancer Inst · NIH-10916214 · Data updated 2026-11-12
This program is looking for fresh ideas and diverse researchers to help improve prostate cancer research, especially for those who are often overlooked, and it will provide support to help them grow their projects and find more funding.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $294,324 |
| NIH project number | 5P50CA272390-02 |
| Project ID | NIH-10916214 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with prostate cancer, particularly those from underrepresented racial and ethnic groups.
✕Less likely to help
Patients with prostate cancer who are not part of the targeted demographic or who do not meet specific eligibility criteria may not benefit from this research.
What this research studies
This program aims to foster new and innovative research approaches to prostate cancer by providing seed funding to promising projects. It focuses on recruiting diverse researchers and ideas to enhance the quality of scientific endeavors in the field. The program will also prioritize applications that address the needs of underrepresented groups in prostate cancer research. Participants will receive support and resources to help them advance their projects and seek further funding opportunities.
Why it matters
Potential benefit: If successful, this research could lead to breakthroughs in prostate cancer treatment and improve patient outcomes.
How similar studies have gone: Previous research initiatives focusing on innovative approaches to cancer treatment have shown promise, indicating that this program's approach could also yield significant advancements.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Freedman, Matthew L — Dana-Farber Cancer Inst
- Study coordinator: Freedman, Matthew L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.